About the Journal
Editorial board | For contributors | Publication and research ethics | Editorial policies
Aims and scope
Drug Target Insights (DTI) is an international, indexed, peer-reviewed, open access, online only journal, published once a year. It covers current developments in all areas of the field of clinical therapeutics, focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal aims to explore the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life and welcomes research on the molecular mechanisms of drug action, including the elucidation of biochemical and cellular pathways that underlie therapeutic effects and mechanistic studies spanning oncology, infectious diseases, metabolic disorders, and related fields. It further addresses clinical therapeutics and real‑world applications, featuring clinical trial data, case reports, and observational studies that evaluate the effectiveness and safety of novel therapies, alongside investigations into patient‑centered outcomes and quality‑of‑life measures
DTI features monothematic sections guided by an dedicated and experienced editor.
Alternative animal models, focused on innovative studies employing non-traditional systems. These include invertebrate and aquatic vertebrate models such as Caenorhabditis elegans, Drosophila melanogaster, zebrafish, and Japanese Medaka, as well as emerging platforms such as organ-on-a-chip technologies and AI-supported model selection tools.
Antimicrobial Resistance, considering contributions dedicated to the antimicrobial resistant infections caused by viruses, bacteria, fungi, protozoa, and helminths, mechanisms of antimicrobial resistance, identification and validation of novel molecular and cellular targets among pathogens and other relevant topics.
Phytotherapeutics and natural products, focused on the health-promoting effects of natural products and phytotherapeutics as promising agents in the prevention and treatment of communicable and non-communicable diseases. Both preclinical (in vitro/in vivo) and clinical (in humans) studies are considered.
Drug Target Insights adopts a single anonymized peer-review process, which means that reviewer identity is not made visible to authors, author identity is visible to reviewers, reviewer and author identity are visible to the editors. Full details on the peer review process and editorial policies can be found here.
DTI publishes new articles as soon as they receive final approval from the authors and are assigned page numbers (online first, as customary now for scientific journals) and then collected in an issue, to guarantee rapid publication times and a timely content availability for its indexing databases. Authors retain the copyright of their article published in Drug Target Insights are free to reproduce and disseminate their work. Full details can be found here.
Articles published by DTI are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Full information on the open access policy can be found here.
All of this journal content is listed on PubMed and freely available via PubMed Central and archived in Portico, which provides permanent archiving for electronic scholarly journals.
